Botulinum toxin for nocturnal bruxism.

Phase 2

Completed

• Conditions: Bruxism; Neurological - Other neurological disorders; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

• Registration Number: ACTRN12618001430224
• Lead Sponsor: Melbourne Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-08-27
• Study Completion: 2020-10-05
• Last Update Posted: 27 March 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

Symptoms of nocturnal bruxism of adequate severity as measured by overnight monitoring.

Exclusion Criteria

Contraindication to botulinum toxin administration, concurrent use of medications affecting muscle relaxation, prior history of severe jaw trauma, orofacial pain of an alternate aetiology, neuromuscular disease, major respiratory disease(s) that may preclude overnight EMG recordings, administration of botulinum toxin for other indication (including cosmetic) within 16weeks of study commencement.

Study & Design

• Study Type: Interventional
• Study Design: Not specified